Prostate Cancer - Results from #980

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. May 2, 2024

Oncological Outcomes in Men With Favorable Intermediate Risk Prostate Cancer Enrolled in Active Surveillance. May 2, 2024

Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial. May 2, 2024

Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy. May 1, 2024

Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting. May 1, 2024

A Community-Based Prostate Cancer Screening and Education Program for Asian American Men in Medically Underserved Communities. May 1, 2024

Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer. May 1, 2024

Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence. May 1, 2024

Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [68Ga]Ga-PSMA-11-PET Examinations. May 1, 2024

Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer. April 30, 2024

Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - A claims data analysis. April 30, 2024

Comparative Effectiveness of Partial Gland Cryoablation Versus Robotic Radical Prostatectomy for Cancer Control. April 30, 2024

A systematic review of cytoreductive prostatectomy outcomes and complications in oligometastatic disease. April 30, 2024

Transperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: The results of a Delphi consensus project. April 30, 2024

Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. April 30, 2024

A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. April 30, 2024

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting. April 30, 2024

Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study. April 29, 2024

Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. April 29, 2024

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study. April 29, 2024

Page 50 of 1437